Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held a meeting with representatives of the Holding Company for Pharmaceuticals, headed by Dr. Ashraf El-Khouly, Managing Director of the Holding Company, and China’s Halo Group, led by Mr. Huang (Jun), Chief Executive Officer of the Group, in the presence of Dr. Tamer El-Hossieny, Vice Chairman of the Authority.
The meeting addressed a number of issues related to the availability of priority and vital pharmaceutical products for Egyptian patients, in addition to reviewing the companies’ future plans in the Egyptian market—particularly with regard to supporting local manufacturing, expanding production capacities, and increasing investment volumes in the pharmaceutical sector.
Dr. El-Ghamrawy opened the meeting by welcoming the delegation and emphasizing the Egyptian Drug Authority’s commitment to strengthening frameworks of cooperation with industry partners from both local and international investors, in a manner that supports the State’s strategy to localize pharmaceutical industries and achieve self-sufficiency in vital and advanced medicinal products.
The Chairman of the Egyptian Drug Authority affirmed that the localization of advanced pharmaceutical industries represents one of the main pillars of the Authority’s strategy, given its pivotal role in enhancing national pharmaceutical security. He highlighted the importance of strategic partnerships aimed at transferring advanced technologies and localizing the manufacturing of oncology medicines and biological products, which are considered national priority areas. He noted that these efforts are being led by the Egyptian Drug City (Gypto Pharma) as a strategic national project.
Dr. El-Ghamrawy further explained that the Egyptian Drug Authority is working to establish a supportive and investment-friendly regulatory environment that attracts serious investments and facilitates registration and manufacturing procedures, while ensuring the availability of safe, effective, and high-quality medicines for Egyptian patients in accordance with the highest internationally recognized standards.
For their part, representatives of the Holding Company for Pharmaceuticals and China’s Halo Group expressed their appreciation for the regulatory and supportive role played by the Egyptian Drug Authority. They underscored the importance of the partnership with Halo Group in transferring advanced pharmaceutical technologies to the Egyptian market, thereby supporting the local pharmaceutical manufacturing ecosystem and enhancing the ability of national companies to compete at both regional and international levels.
The meeting comes within the framework of the State’s and the Egyptian Drug Authority’s strategic orientation toward strengthening national pharmaceutical security and meeting patients’ needs for complex and advanced medicines through local manufacturing, thereby reinforcing Egypt’s position as a leading regional hub for pharmaceutical manufacturing and trade.